Vol. 6 No. 4 (2026): April
Reimbursement Reviews

Asciminib (Scemblix)

decorative image of the issue cover

Published April 1, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses asciminib (Scemblix), 20 mg and 40 mg, film-coated tablets, oral.
  • Indication: For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who are newly diagnosed or who have previously received 1 or more tyrosine kinase inhibitors.